Critical evaluation of the efficacy and tolerability of azilsartan.
Article Details
- CitationCopy to clipboard
De Caterina AR, Harper AR, Cuculi F
Critical evaluation of the efficacy and tolerability of azilsartan.
Vasc Health Risk Manag. 2012;8:299-305. doi: 10.2147/VHRM.S22589. Epub 2012 May 14.
- PubMed ID
- 22661897 [ View in PubMed]
- Abstract
Appropriate control of blood pressure (BP) in hypertensive patients still represents the major therapeutic goal in the treatment of hypertension. Despite the growing attention and wide range of antihypertensive agents available in the clinical scenario, the target of BP below the advised thresholds of 140/90 mmHg is, unfortunately, often unreached. For this reason, the search for new antihypertensive agents is still ongoing. Azilsartan medoxomil, a new angiotensin receptor blocker that has been recently introduced in the clinical arena, represents the eighth angiotensin receptor blocker currently available for BP control. The aim of this paper is to describe the efficacy and safety profile of this new compound, reviewing available data obtained from both pre-clinical and clinical studies.
DrugBank Data that Cites this Article
- Drugs
- Drug Enzymes
Drug Enzyme Kind Organism Pharmacological Action Actions Azilsartan medoxomil Cytochrome P450 2B6 Protein Humans NoSubstrateDetails Azilsartan medoxomil Cytochrome P450 2C8 Protein Humans NoSubstrateDetails - Drug Transporters
Drug Transporter Kind Organism Pharmacological Action Actions Azilsartan medoxomil P-glycoprotein 1 Protein Humans NoInhibitorDetails - Drug Reactions
Reaction Details - Drug Interactions
Drugs Interaction Integrate drug-drug
interactions in your softwareAzilsartan medoxomilFluconazole The metabolism of Azilsartan medoxomil can be decreased when combined with Fluconazole.